Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Vaccine vs SoC in Neoadjuvant TNBC
NCT03554109Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2018
- Primary completion
- Jun 2020
- Modality
- Viral Vector Vaccines, Cell Therapies, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of NANT Neoadjuvant TNBC Vaccine in triple-negative breast cancer (TNBC), sponsored by ImmunityBio, Inc.. Planned start Sep 2018; status: withdrawn.
02
Drugs
NANT Neoadjuvant TNBC Vaccine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03554109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554109.